Annual report pursuant to Section 13 and 15(d)

Discontinued Operations - Assets and liabilities reported as discontinued operations in balance sheet (Details)

v3.21.1
Discontinued Operations - Assets and liabilities reported as discontinued operations in balance sheet (Details) - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Disposal GrDiscontinued operations - current assetsoup, Including Discontinued Operation, Assets, Current, Total $ 181,000 $ 1,550,000
Discontinued operations - current liabilities 1,960,000 2,080,000
U.S. commercialization activities | Discontinued operations    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Receivables 0 555,000
Inventory 0 435,000
Prepaid expenses and other current assets 181,000 560,000
Disposal GrDiscontinued operations - current assetsoup, Including Discontinued Operation, Assets, Current, Total 181,000 1,550,000
Accounts payable 1,515,000 585,000
Accrued clinical trials expenses 80,000 140,000
Accrued sales allowances 61,000 809,000
Other accrued liabilities 304,000 546,000
Discontinued operations - current liabilities 1,960,000 2,080,000
Non-cash stock-based compensation expenses $ 100,000 $ 100,000